Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Decreases By 64.2%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 808,800 shares, a drop of 64.2% from the September 15th total of 2,260,000 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average daily volume of 21,650,000 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 21,650,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.1% of the company’s shares are short sold.

Aspire Biopharma Stock Performance

Shares of ASBP stock opened at $0.34 on Friday. The business’s 50 day moving average is $0.43. Aspire Biopharma has a 52 week low of $0.20 and a 52 week high of $15.80.

Aspire Biopharma (NASDAQ:ASBP) last announced its earnings results on Wednesday, August 13th. The company reported ($0.04) EPS for the quarter.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Aspire Biopharma to a “strong sell” rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Trading of Aspire Biopharma

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC raised its holdings in Aspire Biopharma by 625.8% during the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares during the period. Optivise Advisory Services LLC raised its holdings in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after purchasing an additional 128,660 shares during the last quarter. Crewe Advisors LLC raised its holdings in shares of Aspire Biopharma by 100.0% in the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after purchasing an additional 313,427 shares during the last quarter. Finally, Procyon Advisors LLC raised its holdings in shares of Aspire Biopharma by 558.3% in the second quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock valued at $174,000 after purchasing an additional 549,911 shares during the last quarter. 19.17% of the stock is currently owned by institutional investors and hedge funds.

Aspire Biopharma Company Profile

Aspire Biopharma Holdings, Inc, early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management.